Steven D Goldby
CIK 1216626 · Chairman of the Board · last filed 2019-05-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LNDC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3100 CENTRAL EXPRESSWAY
SANTA CLARA, CA 95051
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Director | 73,137 | $8.76 | $640.7K | $224.8K | 23 | 2019-05-30 |
| ACCL | Director | 7,950 | $2.61 | $20.7K | $0 | 3 | 2011-08-05 |
| SYMYX TECHNOLOGIES INC (SMMX) Delisted | Chairman of the Board | 64,845 | — | — | $0 | 7 | 2009-06-15 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | Director | — | $18.62 | — | $0 | 2 | 2008-06-06 |
Recent Filings · Page 2 of 4
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-06-01 | LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Exer (M) | — | $0 | EDGAR |
| 2016-05-31 | LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Exer (M) | +3,475 | $39.8K | EDGAR |
| 2015-10-23 | LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Mixed | +10,000 | $67.2K | EDGAR |
| 2015-05-29 | LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Exer (M) | +4,219 | $60.3K | EDGAR |
| 2013-06-10 | LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Exer (M) | — | $0 | EDGAR |
| 2013-05-20 | LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Exer (M) | +1,667 | $0 | EDGAR |
| 2012-05-23 | LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Exer (M) | +1,667 | $0 | EDGAR |
| 2012-05-18 | LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Exer (M) | — | $0 | EDGAR |
| 2011-12-27 | LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Exer (M) | +3,333 | $18.8K | EDGAR |
| 2011-08-05 | ACCL | Grant (A) | +6,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.